Starting Wegovy: What to Expect in the First Month (Patient Onboarding Guide)

The honest answer: the first month on Wegovy is the 0.25 mg starting dose — a deliberately sub-therapeutic level designed for gastrointestinal tolerability, not weight loss. Expect minimal scale movement in weeks 1-4. The most common side effects (nausea, vomiting, diarrhea, constipation) peak in this window per STEP-1 pivotal trial data and improve substantially after the dose-escalation step at week 5. Real weight loss begins around weeks 8-12, accelerates through weeks 16-28, and reaches the STEP-1 pivotal magnitude of roughly −14.9% body weight at 68 weeks. Per the Wegovy FDA prescribing information^[6], the starting dose of 0.25 mg once weekly for weeks 1-4 is followed by a 16-week titration ladder: 0.5 mg weekly at weeks 5-8, 1.0 mg weekly at weeks 9-12, 1.7 mg weekly at weeks 13-16, and 2.4 mg weekly from week 17 onward as the maintenance dose. The purpose of the 0.25 mg starting step is not pharmacologic weight loss — it is GI receptor acclimation. The Marathe 2013 Peptides review^[4] documents that GLP-1 receptor agonism slows gastric emptying via vagal afferent pathways, and that the gastric-emptying delay (which is the mechanism behind both the satiety effect and the nausea/vomiting tolerability signal) is dose-dependent and subject to tachyphylaxis — receptor desensitization develops over weeks of repeated exposure. Starting at a low dose lets the GI receptors desensitize gradually so that the therapeutic 2.4 mg dose, when reached at week 17, is tolerable rather than overwhelming. The STEP-1 pivotal RCT (Wilding 2021 NEJM^[1]) followed this same 16-week titration, and the time-course of GI adverse events in the trial confirms what patients experience: nausea, vomiting, diarrhea, and constipation peak during the dose-escalation weeks and taper as the patient settles into a steady dose. For an interactive view of the week-by-week trajectory, see our GLP-1 side-effect timeline tool — it shows the expected nausea/vomiting/fatigue curve at each titration step and identifies the typical taper window.

At a glance — what to expect in weeks 1-4

• Dose: 0.25 mg subcutaneous once weekly for weeks 1-4 per the FDA label^[6]. This is a sub-therapeutic starting dose; the therapeutic maintenance dose is 2.4 mg, reached at week 17.
• Weight loss in weeks 1-4: negligible to minimal — typically 0-3 lb (~0-1.5 kg). STEP-1 pivotal-trial weekly weight-curve supplementary data shows the steepest weight-loss slope begins around weeks 8-12 (after the first two titration steps) and continues through weeks 16-28^[1].
• Side effects in weeks 1-4: nausea is the most common; STEP-1 reported pooled nausea 44.2% (vs 16.1% placebo) over the full 68 weeks^[1], with the AE incidence concentrated in the titration weeks. Vomiting 24.8% (vs 6.5%), diarrhea 31.5% (vs 15.9%), constipation 23.4% (vs 9.5%) — pooled across STEP 1, 3, and 4 per the FDA label^[6].
• Injection site: abdomen, thigh, or upper arm; rotate sites weekly per the FDA label^[6]. See our injection-site guide for technique.
• Refrigeration: store unused pens at 2°C-8°C (36°F-46°F). After first use, pens can be stored at room temperature (up to 30°C / 86°F) or refrigerated for up to 28 days; discard after 28 days regardless. Do not freeze; protect from light.
• Missed dose rule: if you remember within 5 days of the missed dose, take it as soon as possible. If more than 5 days have passed, skip the missed dose and resume the regular weekly schedule. Do not double-dose.
• Week 5 escalation: 0.25 mg → 0.5 mg. Expect a transient bump in nausea/GI symptoms for 1-2 weeks after escalation, then improvement as receptors acclimate to the new dose.
• Call your prescriber if: severe upper- abdominal pain radiating to the back (possible pancreatitis — §5.2 of label^[6]), persistent vomiting with dehydration signs, signs of gallbladder disease (RUQ pain, jaundice — §5.4), severe allergic reaction, or hypoglycemia symptoms in patients on insulin or sulfonylureas (§5.7).

Why Wegovy starts at 0.25 mg (the titration logic)

Wegovy is semaglutide — a long-acting GLP-1 receptor agonist with a half-life of approximately 165 hours (~7 days). The Lau 2015 J Med Chem discovery paper^[3] describes the structural modifications to native human GLP-1 that produce this long half-life: a single amino-acid substitution (Aib at position 8) makes the molecule resistant to dipeptidyl peptidase-4 (DPP-4) degradation, and a C18 fatty diacid attached via a gamma-Glu spacer enables strong albumin binding. The result is a peptide that circulates in plasma with weekly dosing kinetics — but it also means the therapeutic dose, if administered at the start, would saturate GLP-1 receptors abruptly and produce intolerable nausea and vomiting in most patients.

The titration ladder exists to manage this. Per §2.3 of the Wegovy FDA prescribing information^[6], the dose escalation is:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

The first month — the 0.25 mg step — is approximately one- tenth of the therapeutic 2.4 mg maintenance dose. The Marathe 2013 Peptides mechanism review^[4] describes the physiological basis: GLP-1 receptors in the gastric pyloric sphincter and the area postrema (the brain's chemoreceptor trigger zone for nausea) are the primary sources of GI side effects. Both pathways undergo tachyphylaxis — receptor desensitization — with repeated exposure. The 0.25 mg starting step is calibrated to produce enough receptor engagement to begin desensitization without producing severe nausea or vomiting in most patients. By the time the patient reaches the 2.4 mg maintenance dose at week 17, the GI receptors have been progressively acclimated across four intermediate dose steps and the therapeutic dose is tolerable.

The trade-off is straightforward: the first month is not a weight-loss month. It is a tolerability month. Patients who expect rapid scale movement in weeks 1-4 are setting themselves up for disappointment and premature discontinuation. The STEP-1 pivotal trial^[1] used this same 16-week titration, and the trial outcome ( −14.9% body weight at 68 weeks vs −2.4% placebo) is what the slow titration buys.

Weeks 1-4: what to expect on the scale (and why it's near-zero)

The honest expectation for weight loss in weeks 1-4 on 0.25 mg semaglutide is 0-3 lb (~0-1.5 kg), and most of that may be water-weight shifts from reduced food intake rather than fat loss. The weekly weight-curve supplementary data from the STEP-1 trial^[1] shows the steepest weight-loss slope begins around weeks 8-12 — after the patient has escalated through 0.5 mg and reached 1.0 mg — and continues accelerating through weeks 16-28 as the patient reaches and stabilizes on the 2.4 mg maintenance dose. Weight loss in weeks 1-4 is best understood as a leading indicator of GI tolerability rather than a leading indicator of treatment success.

Two practical framings help patients hold this in mind. First, the 0.25 mg starting dose is approximately one-tenth of the maintenance dose by milligram, and roughly one-tenth of the therapeutic appetite-suppression effect by clinical observation. Expecting one-tenth of the eventual weight loss in the first month is reasonable; expecting half of it is not. Second, the appetite suppression itself is often subtle in weeks 1-4 — many patients describe “earlier fullness” or “less interest in seconds” rather than the dramatic appetite reduction that becomes more obvious at the 1.0 mg and higher doses. If you do not feel much in the first month, that is consistent with the pharmacology, not evidence that the medication is not working.

See our GLP-1 side effects — what the trials actually showed for the full STEP-1 / STEP-3 / STEP-4 adverse-event tables with the time-course annotations.

The side-effect timeline in weeks 1-4 (link to interactive tool)

Per §6.1 of the Wegovy FDA label^[6] (pooled across STEP 1, 3, and 4), the most common adverse reactions are gastrointestinal:

• Nausea: 44.2% (vs 16.1% placebo) — onset typically within 1-3 days of first dose
• Diarrhea: 31.5% (vs 15.9% placebo)
• Vomiting: 24.8% (vs 6.5% placebo)
• Constipation: 23.4% (vs 9.5% placebo) — typically appears in week 2 onward
• Abdominal pain: 20.0% (vs 10.3% placebo)
• Headache: 14.5% (vs 9.7% placebo)
• Fatigue: 11.4% (vs 4.6% placebo)
• Dyspepsia: 9.2% (vs 2.6% placebo)

These are pooled rates across the entire 68-week trial. In practice, the rates are highest during the first weeks at each new dose step and lower in between, as the Marathe 2013 Peptides mechanism review^[4] predicts from receptor tachyphylaxis. The typical week-by-week pattern in the first month:

• Days 1-3: mild-to-moderate nausea, often starting 12-48 hours after the first injection. Mild fatigue common.
• Days 3-7: nausea often persists at lower intensity. Reduced appetite begins (the “food noise” reduction effect). Constipation may begin as fiber intake drops with reduced food volume.
• Week 2: some patients see GI symptoms taper before the next injection; others continue at low-grade baseline. Second dose may produce a milder repeat of week 1.
• Week 3: partial receptor desensitization becoming evident — GI symptoms typically milder than week 1 for most patients.
• Week 4: last week at 0.25 mg before escalation; many patients describe this as the most tolerable week of the first month.

For a personalized week-by-week view of your expected trajectory, including a comparison to other GLP-1 medications, see our interactive GLP-1 side-effect timeline. The tool plots typical nausea, fatigue, and appetite- suppression curves at each dose step and shows where the taper windows fall. For practical nausea management, see our GLP-1 nausea management practical guide — meal-size, hydration, and food-temperature levers backed by the pivotal-trial supplementary data.

Practical logistics: refrigeration, injection sites, technique

Wegovy is supplied as a single-dose pre-filled pen at each dose strength. The pen is dose-locked at the strength printed on the label — the 0.25 mg pen delivers only 0.25 mg per injection, the 0.5 mg pen only 0.5 mg, and so on through 2.4 mg. There is no dial; the patient cannot accidentally administer more or less than the labeled dose. This is a deliberate safety design.

Refrigeration and storage per the FDA label^[6]:

• Unused pens: store refrigerated at 2°C-8°C (36°F-46°F). Do not freeze. Protect from light by keeping the pen in its carton until use. Do not use pens that have been frozen.
• After first use: the pen may be stored at room temperature (up to 30°C / 86°F) or refrigerated for up to 28 days. After 28 days, discard the pen even if unused medication remains.
• Travel: for trips longer than a few hours in warm weather, use an insulated travel pouch or a small insulated cooler with ice packs (not direct contact with the pen). Wegovy is tolerable up to 30°C but not above — avoid leaving pens in a hot car, on a sunny windowsill, or in checked airline luggage (cargo holds can drop below freezing).

Injection sites per §2.4 of the FDA label^[6]: the abdomen (avoiding a 2-inch radius around the navel), the front of the thigh, or the upper outer arm. Rotate the injection site each week — do not use the same site two weeks in a row. The site choice does not change the drug's pharmacology in any clinically meaningful way; it is purely about avoiding local skin reactions (redness, induration, lipohypertrophy) from repeated injections at the same site. See our injection-site guide for technique illustrations and rotation patterns.

Technique for the once-weekly injection:

• Wash hands with soap and water.
• Remove the pen from the refrigerator 15-30 minutes before injection to let it reach room temperature — cold injections sting more.
• Check the dose window on the pen to confirm correct dose strength and that the solution is clear and colorless.
• Wipe the chosen injection site with an alcohol swab.
• Pinch a fold of skin, insert the pen needle straight in at 90 degrees, press the dose button, and hold for 6 seconds (count slowly) before withdrawing — this ensures full dose delivery.
• Dispose of the used pen in a sharps container; do not put it in regular trash.

Day of week: pick the day that fits your schedule and stay on it. Most patients pick a quieter day (often a weekend morning) because of the higher chance of post-injection GI symptoms in the first 24-48 hours of the first few doses.

Missed dose: the 5-day window rule

Per §2.3 of the Wegovy FDA label^[6], the missed- dose rule is straightforward and is one of the clearest instructions in the prescribing information:

• If less than 5 days have passed since the missed dose: take the missed dose as soon as you remember. Then resume your regular weekly schedule on the originally scheduled day.
• If more than 5 days have passed since the missed dose: skip the missed dose entirely. Take your next dose on the next regularly scheduled day. Do not double your next dose to make up for the missed one.

The 5-day window reflects semaglutide's ~165-hour half-life (Lau 2015^[3]). Within 5 days of a missed dose, semaglutide plasma concentrations remain in a range where taking the delayed dose maintains steady-state. Beyond 5 days, concentrations have dropped enough that taking the delayed dose risks producing a steep concentration rise when combined with the next regularly scheduled dose — and that rise reproduces the receptor saturation that the slow titration was designed to avoid.

For an interactive missed-dose decision tool that walks through the 5-day rule and applies it to Wegovy, Ozempic, Zepbound, and Mounjaro, see our GLP-1 missed-dose guide tool.

If you miss multiple consecutive doses (more than 2 weeks without a dose): contact your prescriber. You may need to restart at 0.25 mg and re-titrate from the beginning — the receptor desensitization you built up in the original titration is lost over weeks of no exposure, and restarting at the higher dose can reproduce severe first-week GI side effects.

Concurrent medications and oral-drug timing

A widely-repeated piece of advice online is that GLP-1 patients must space oral medications by 60 minutes from the injection. This is not a requirement for injectable Wegovy. The 60-minute oral-spacing rule applies to oral semaglutide (Rybelsus) — a different product with a strict 30-minute fasting window before and after the dose because the salcaprozate sodium absorption enhancer requires an empty stomach. Injectable Wegovy has no such oral- timing requirement.

What §7 of the Wegovy FDA label^[6] does say is that semaglutide delays gastric emptying and that this could theoretically affect the absorption of co-administered oral medications. Clinical-trial drug-interaction studies tested oral contraceptives, metformin, digoxin, warfarin, and atorvastatin — none showed clinically significant changes in pharmacokinetics. The label does not recommend any specific oral-medication spacing.

Categories of medications that do warrant prescriber discussion before starting Wegovy:

• Insulin and sulfonylureas (glyburide, glipizide, glimepiride) — risk of hypoglycemia. Per §5.7 of the label^[6], prescribers typically reduce insulin or sulfonylurea doses when starting semaglutide. Patients on these medications should self-monitor blood glucose during the first month.
• Oral medications with narrow therapeutic windows(warfarin, certain antiepileptics, certain immunosuppressants) — while the trial data show no clinically significant PK changes, individual patients may experience absorption variability. Monitor INR for warfarin patients.
• Other GLP-1 receptor agonists or DPP-4 inhibitors (e.g., liraglutide, exenatide, sitagliptin, linagliptin) — these should not be co-administered. Discontinue the prior GLP-1 or DPP-4 inhibitor before starting Wegovy.
• Medications causing pancreatitis — review for valproate, didanosine, pentamidine, and others with known pancreatitis associations. Risk-benefit discussion with prescriber.

Categories where the “take with food” instruction matters more than usual: medications with gastric-emptying-sensitive absorption (some opioid analgesics, levothyroxine timing relative to food) may show small absorption changes. Most patients can continue these as prescribed; flag any new symptoms (under-treatment or toxicity) to your prescriber.

Week 5: the first dose escalation

At week 5, the dose escalates from 0.25 mg to 0.5 mg — a doubling. Per the FDA label^[6], this is the standard schedule for all patients on the titration ladder, and most patients move through this step without difficulty. Expect:

• A transient bump in GI symptoms (nausea, fatigue) for 1-2 weeks after the dose change, mirroring what you experienced in week 1 at a slightly higher intensity. The Marathe 2013 mechanism review^[4]attributes this to the increased GLP-1 receptor occupancy before tachyphylaxis re-equilibrates at the new dose.
• Increased appetite suppression becoming more noticeable. Many patients describe the appetite reduction at 0.5 mg as the first clearly clinical effect, where 0.25 mg felt subtle.
• Possible weight-loss acceleration beginning in weeks 6-8. The STEP-1 weight curve^[1] begins to show a steeper downward slope around this window.

If the week-5 escalation is intolerable — severe nausea, vomiting, dehydration, or inability to keep food/fluids down for more than 24-48 hours — contact your prescriber. The FDA label permits dose-step delays: the prescriber may keep you on 0.25 mg for an additional 4 weeks before retrying the 0.5 mg step, or may have you take the next 0.5 mg dose 2 weeks after the last 0.25 mg dose rather than 1 week. The titration ladder is a default schedule, not an obligatory one. Slower titration in patients with severe GI intolerance is well-documented and does not necessarily compromise the eventual weight-loss outcome.

For an interactive titration planner that lets you map out the dose-by-week schedule with custom delay options, see our GLP-1 titration planner.

When to call your prescriber

Most first-month side effects are GI symptoms that resolve with conservative management. However, several presentations require immediate clinician contact per the FDA label^[6] warnings sections:

• Severe upper-abdominal pain (often radiating to the back), with or without nausea and vomiting — possible acute pancreatitis (§5.2). Discontinue Wegovy and seek immediate evaluation.
• Right-upper-quadrant abdominal pain, jaundice, fever, or pale stools — possible acute gallbladder disease or cholecystitis (§5.4). Wegovy is associated with increased gallbladder-disease incidence vs placebo in the STEP trials.
• Persistent vomiting with dehydration signs(dark urine, dizziness on standing, dry mouth, no urination for 8+ hours) — acute kidney injury risk (§5.5). Stop oral fluids only if also unable to keep clear liquids down; otherwise sip electrolyte solution and call your prescriber the same day.
• Severe allergic reaction (anaphylaxis or angioedema — swelling of lips/tongue/throat, difficulty breathing, generalized rash) — call 911 immediately. Do not take the next dose. Notify your prescriber.
• Hypoglycemia symptoms (shaking, sweating, confusion, palpitations) in patients on insulin or sulfonylureas — per §5.7. Treat with 15 g of fast-acting carbohydrate (4 oz juice, 4 glucose tablets), recheck in 15 minutes, repeat if needed. Notify your prescriber the same day to adjust the concomitant diabetes medication.
• Lump or swelling in the neck, hoarseness, persistent difficulty swallowing — possible medullary thyroid carcinoma signal (§5.1 boxed warning). Wegovy is contraindicated in patients with personal/family history of MTC or multiple endocrine neoplasia 2A/2B. Discontinue and seek evaluation.
• Suicidal thoughts, mood changes, or worsening depression — flag to your prescriber. Per §5.8, GLP-1 receptor agonists carry a label warning to monitor for depression and suicidal ideation, particularly in patients with prior psychiatric history.
• Vision changes in patients with type 2 diabetes — possible diabetic retinopathy complications (§5.6).

For the broader GLP-1 side-effect Q&A hub with management algorithms by symptom, see our GLP-1 side-effect questions answered hub.

What to eat in the first month

The first-month eating pattern matters more for tolerability than for weight loss. The two empirically helpful patterns across the STEP-trial supplementary data and patient-reported outcomes:

• Smaller, more frequent meals (4-5 small rather than 2-3 large). Reduced gastric volume per sitting accommodates the delayed gastric emptying without producing the “stuck” feeling that triggers nausea.
• Lower fat content per meal (≤25-30 g fat). Dietary fat further slows gastric emptying; the additive effect with semaglutide produces the strongest nausea trigger. Save higher-fat meals for later in titration when receptors have acclimated.
• Adequate protein (~25-30 g per meal). The appetite suppression makes it easy to under-eat protein, and the resulting lean-mass loss is the most common preventable downside of GLP-1 therapy. See our what to eat on a GLP-1 — protein-anchored eating guide for the protein-target framework.
• Hydration: aim for ~2-3 L of fluid daily. The appetite suppression can blunt thirst cues, and the GI symptoms (nausea, occasional diarrhea) increase fluid losses. Dehydration is the most common reason for first-month emergency-room visits in early GLP-1 patients.
• Avoid foods that triggered GI symptoms in week 1.Common triggers: fried foods, very spicy foods, large dairy-fat servings (heavy cream, full-fat ice cream), carbonated beverages, alcohol. Reintroduce gradually after the week-5 escalation if interested.
• Constipation prevention: the appetite reduction usually drops fiber intake, and the gastric- emptying delay slows GI transit further. Maintain ~25-30 g/day fiber (vegetables, berries, oats, beans) and ~2-3 L fluid. Magnesium citrate at bedtime (~200-400 mg) is a low-risk option some patients find helpful; discuss with prescriber if dependent.

Frequently asked questions

Below are the questions WLR receives most often from patients starting Wegovy. For the full FAQ hub with management algorithms, see GLP-1 side effect questions answered.

Related research and tools

• GLP-1 side-effect timeline tool — the interactive companion to this article. Plots week-by-week nausea, fatigue, and appetite-suppression curves at each titration step.
• GLP-1 titration planner — map your dose-by-week schedule with custom delay options if you need a slower titration than the default.
• GLP-1 missed-dose guide — interactive decision tool for the 5-day window rule, applied to Wegovy, Ozempic, Zepbound, and Mounjaro.
• GLP-1 nausea management practical guide — meal-size, hydration, food-temperature, and medication-timing levers for the nausea-dominant first month.
• Where to inject semaglutide / tirzepatide — injection-site selection, rotation pattern, and technique with the 6-second hold for full dose delivery.
• GLP-1 side effects — what the trials actually showed — full STEP-1 / STEP-3 / STEP-4 adverse-event tables with time-course annotations.
• What to eat on a GLP-1 — protein-anchored eating guide — the ~25-30 g per-meal protein framework that prevents lean-mass loss during appetite-suppressed weight loss.
• Wegovy (semaglutide) drug profile — STEP-1 magnitude reference (−14.9% body weight at 68 weeks), STEP-5 long-term durability (−15.2% at 104 weeks), full label warnings.

Important disclaimer. This article is educational and does not constitute medical advice. Wegovy is a prescription medication; the appropriate starting dose, titration schedule, and management of side effects must be determined by the prescribing clinician based on individual patient factors including comorbidities, concurrent medications, and tolerability. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome 2A/2B must NOT use Wegovy (boxed warning, §5.1 of the FDA label). Patients with a history of pancreatitis, gallbladder disease, severe gastroparesis, diabetic retinopathy, or active suicidal ideation require individualized prescriber assessment. The titration schedule described here is the FDA-approved default; prescribers may modify the schedule for patients with severe GI intolerance. Pregnancy: discontinue Wegovy at least 2 months before a planned pregnancy per §8.1 of the label. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-23; the Wegovy DailyMed SetID was verified live on the same date.

Last verified: 2026-05-23. Next review: every 6 months, or sooner if the FDA label is updated or new STEP- program data are published.